Doyle Janeen Noel

Doyle Janeen Noel is listed in filings as Chief Corp. & Bus. Dev. Ofcr at Janux Therapeutics, Inc.. This profile follows SEC Form 4 activity through Jun 4, 2026, including sale activity. Recent filings connect the profile to Janux Therapeutics, Inc. (JANX). The current snapshot covers public activity from Jun 4, 2025 to Jun 4, 2026. Reported amounts are shown as $56.9K to $3.9M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.